Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Trial Profile

Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary) ; Idarubicin
  • Indications Acute myeloid leukaemia; Myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 07 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
    • 02 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top